Are you finding it difficult to find the right physiologically -relevant animal model which is able to engraft your cancer xenografts and PDXs?
Our novel SRG Rat model is a unique platform for xenograft and PDX drug efficacy studies.
Created through knockout mutations in the Rag2 and Il2rgamma genes that result in a loss of mature B, T, and NK cells, the SRG Rat has an immunodeficient phenotype ideal for the engraftment of human tissue.
Taking advantage of the Sprague Dawley background and the larger sized xenograft host, the SRG is an ideal model for combining efficacy, pharmacokinetic (PK), biomarker, and toxicology-related endpoints.
Boost your preclinical oncology research with our SRG Rat model delivered directly from our colony maintained at the Charles River Labs GEMS facility at the highest health standard.
Contact us to learn more.